Eisai’s Small Molecule Analog Reduced Inflammation and Injury in Mice with IBD, Study Shows

Eisai’s Small Molecule Analog Reduced Inflammation and Injury in Mice with IBD, Study Shows
A small molecule analog developed by Eisai, called ER-464195-01,  may be a potential therapy for patients with inflammatory bowel disease (IBD) by reducing infiltration of inflammatory cells, according to researchers. Their study, “Calreticulin and integrin alpha dissociation induces anti-inflammatory programming in animal models of inflammatory bowel disease,” was published in the journal Nature Communications. IBD is a group of diseases that are characterized by repeated inflammation in the lining of the large or small intestines. One of the major processes in the development of IBD is the recruitment and infiltration of white blood cells to areas of inflammation, which leads to more inflammation and causes disease worsening. It is well known that the activated integrin α sub-units (ITGAs), a group of proteins that are expressed on the surface of many white bloods cells, are the key to the migration and action of these cells. The treatment of IBD patients using antibodies raised against the cell surface integrin α 4 (ITGA4) has been shown to be effective. Calreticulin (CRT) — a calcium-binding protein — is a partner in the activation of ITGAs. However, the relationship between their interaction and how they contribute to IBD has been largely unknown. Japanese researchers, seeking to understand their relationship, conducted a screening assay to identify a compound that would dissociate CRT and ITGA4 interaction using Eisai's compound library. They identified ER-464195-01 as a small molecule that sup
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *